AbbVie Inc. (NYSE:ABBV) agreed to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) on March 24, 2024.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.3 USD | +0.61% | -0.42% | +506.53% |
04-02 | North American Morning Briefing : Stocks Seen -2- | DJ |
04-01 | HC Wainwright Downgrades Landos Biopharma to Neutral From Buy | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
160.6 USD | -1.22% | -0.64% | 287B | ||
22.3 USD | +0.61% | -0.42% | 69.3M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+506.53% | 69.3M | |
+22.70% | 46.4B | |
-1.46% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.23% | 26.01B | |
-19.68% | 19.52B | |
+26.63% | 12.43B | |
+0.09% | 12.18B | |
-0.53% | 12.13B |
- Stock Market
- Equities
- LABP Stock
- News Landos Biopharma, Inc.
- AbbVie Inc. agreed to acquire Landos Biopharma, Inc. on March 24, 2024.